LadRx (STU:CX5) EBIT per Share : €-7.35 (TTM As of Dec. 2023)

View and export this data going back to 1986. Start your Free Trial

What is LadRx EBIT per Share?

LadRx's EBIT per Share for the three months ended in Dec. 2023 was €-1.63. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €-7.35.

During the past 3 years, the average EBIT per Share Growth Rate was 26.40% per year. During the past 5 years, the average EBIT per Share Growth Rate was 22.40% per year. During the past 10 years, the average EBIT per Share Growth Rate was 39.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for LadRx's EBIT per Share or its related term are showing as below:

STU:CX5' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -63.4 Med: 12 Max: 65.1
Current: 26.4

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of LadRx was 65.10% per year. The lowest was -63.40% per year. And the median was 12.00% per year.

STU:CX5's 3-Year EBIT Growth Rate is ranked better than
77.99% of 1313 companies
in the Biotechnology industry
Industry Median: 3.6 vs STU:CX5: 26.40

LadRx's EBIT for the three months ended in Dec. 2023 was €-0.81 Mil.

LadRx EBIT per Share Historical Data

The historical data trend for LadRx's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LadRx EBIT per Share Chart

LadRx Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-21.25

-16.18

-14.07

-9.57

-7.18

LadRx Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT per Share	Get a 7-Day Free Trial															-1.74	-2.19	-1.93	-1.59	-1.63

LadRx EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

LadRx's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-3.506	/	0.488
=	-7.18

LadRx's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-0.809	/	0.495
=	-1.63

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-7.35

LadRx (STU:CX5) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

LadRx EBIT per Share Related Terms

Thank you for viewing the detailed overview of LadRx's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

LadRx (STU:CX5) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LadRx Corp (STU:CX5) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

LADX:USA

Address

11726 San Vicente Boulevard, Suite 650, Los Angeles, CA, USA, 90049

Website

https://www.ladrxcorp.com

LadRx Corp operates as a biopharmaceutical research and development company in the healthcare sector of the United States. It is focused on the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company develops Aldoxorubicin, which is meant to cure soft tissue sarcoma, a kind of tumor. It also develops Arimoclomol which is in development in Niemann Pick disease Type C (NPC) and Gaucher disease.

LadRx (STU:CX5) Headlines

No Headlines